Tablet Formulation Development: Step-by-Step Process Guide

Tablet formulation development is one of the most common pharmaceutical development activities, yet it is also one of the most likely to face avoidable delays: poor flow in scale-up, dissolution failures after packaging changes, stability-driven assay drift, or unexpected impurity trends. The best teams treat tablet development as a structured engineering process—not trial-and-error.

This guide walks through a step-by-step approach that aligns formulation decisions to manufacturability, analytical strategy, stability, and CTD-ready documentation.

Tablet formulation development: the CQAs and CPPs you must define early

Before optimization, define what “success” means in measurable terms. In tablet formulation development, common critical quality attributes (CQAs) include:

• Assay and content uniformity
• Related substances / impurity profile
• Dissolution or release profile (and discriminatory power of the method)
• Disintegration (as applicable), hardness, friability
• Moisture content (where relevant) and appearance

And the most common critical process parameters (CPPs) that drive those CQAs include:

• Blend order and mixing time, especially lubricant addition time
• Granulation endpoint (if wet granulation), binder addition strategy
• Drying time/temperature and residual moisture targets
• Milling screen size and particle size control
• Compression force, speed, dwell time, and tooling condition

If you can’t trace a CQA back to the variables that control it, scale-up becomes guesswork.

Step 1 — Define the target product profile (TPP) and regulatory path

Before you touch excipients, clarify:

• Target market(s) and climatic zone strategy (impacts stability conditions; see ICH Q1A(R2))
• Dosage strength(s) and dose range
• Release profile (IR vs MR)
• Patient considerations (swallowability, scoring, taste)
• Manufacturing site constraints and equipment
• Regulatory pathway (generic vs innovation, region-specific requirements)

These inputs control the acceptable formulation space and the development “design envelope.”

Step 2 — Preformulation: understand the API and risks

Tablet development starts with API understanding. Typical preformulation activities include:

• Solubility and pH solubility profile
• Solid-state characterization (polymorphism, hydrates)
• Particle size distribution and surface area
• Hygroscopicity and moisture sensitivity
• Compatibility risks (acid/base interactions, peroxide sensitivity, Maillard reaction)

This phase informs whether you need:

• Solubilization approaches
• Particle engineering
• Protective packaging
• Antioxidants, chelators, or pH modifiers (where justified)

Tablet formulation development: excipient risk controls (peroxides, moisture, reactivity)

Many tablet stability and impurity issues are “born” from excipient variability rather than the API alone. Build risk controls early:

• Request peroxide/impurity profiles for relevant excipients
• Define acceptable moisture limits and storage conditions for hygroscopic materials
• Consider compatibility with reducing sugars (Maillard-type risk) where applicable
• Align incoming material controls to your risk assessment and vendor qualification strategy

These controls reduce late-stage stability surprises that can impact ICH Q1A(R2) programs.

Step 3 — Excipient selection and compatibility screening

In tablet formulation development, excipient choice is not only about compressibility; it also impacts:

• Impurity formation (e.g., reactive excipients)
• Dissolution robustness across lots
• Stability under humidity and heat
• Processability (granulation, blending, lubrication)

Typical screening considerations:

• Filler/binder system (e.g., MCC, lactose, DCP)
• Disintegrant selection and level
• Lubricant type and mixing sensitivity
• Glidant needs for flow
• Film coat needs (light protection, taste masking, identification)

Compatibility studies often run in parallel with method development so that any new degradants can be detected and tracked with a stability-indicating method (ICH Q2(R1) principles).

Step 4 — Choose the manufacturing approach (direct compression vs granulation)

A core decision is the process route:

Direct compression (DC)

Pros:

• Simple process, fewer variables
• Lower cost and faster scale-up

Risks:

• Flow and blend uniformity challenges at scale
• Content uniformity risk for low-dose actives
• Lubrication sensitivity

Wet granulation

Pros:

• Improved flow, compressibility, uniformity
• Better robustness for challenging APIs

Risks:

• Heat/moisture exposure
• More process parameters to control

Dry granulation / roller compaction

Pros:

• Avoids moisture
• Suitable for moisture-sensitive APIs

Risks:

• Compaction-related dissolution changes
• Ribbon and granule variability if not controlled

The “best” approach is the one that delivers consistent CQAs with manageable CPPs and is transferable to commercial equipment.

Step 5 — Prototype builds and optimization cycles

Prototype studies should be structured and hypothesis-driven:

• Identify key CQAs: assay, content uniformity, dissolution, hardness, friability, disintegration, impurity limits
• Link CQAs to formulation and process variables
• Use designed experiments where needed (not necessarily large DoE, but disciplined testing)

Optimization targets include:

• Robust dissolution across pH, media, and agitation conditions
• Compression window (hardness vs friability vs disintegration)
• Lubrication robustness (avoid dissolution slow-down from overmixing)

Tablet formulation development: dissolution method strategy that prevents rework

Dissolution is often the most time-consuming “surprise failure” during scale-up. A robust approach:

• Develop a method that is discriminatory (can detect meaningful differences)
• Evaluate sensitivity to API PSD, lubrication time, and compression force
• Confirm robustness across media conditions relevant to your product and claims
• Define how you will handle dissolution drift during stability (trend-based decisions)

When dissolution is treated as an afterthought, teams often re-run prototype cycles late—right when timelines are tight.

Step 6 — Analytical strategy: methods that support development and stability

Development speed depends on analytics. In tablet programs:

• Dissolution method development should reflect discriminatory power and be fit for purpose
• Assay and related substances methods must be stability-indicating
• Validation should follow ICH Q2(R1) for accuracy, precision, linearity, specificity, etc., in line with program stage

An underpowered method will hide issues until late—causing rework and missed timelines.

Step 7 — Stability planning integrated with formulation and packaging

Stability is not a late step. In tablet formulation development, stability should be integrated early:

• Select container–closure system and justify barrier properties
• Plan long-term and accelerated studies per ICH Q1A(R2)
• Monitor dissolution and impurities for early drift

Stability findings often drive:

• Coat selection and thickness
• Moisture protection (desiccant, blister type)
• Antioxidant strategy (where justified)

Tablet formulation development: packaging decisions that protect shelf-life

Packaging is part of the stability system. For tablets, consider:

• Moisture barrier needs (bottle resin, liner, desiccant, blister type)
• Light sensitivity (coat selection, foil, secondary packaging)
• Mechanical protection (friable tablets, shipping conditions)

Align packaging selection with stability conditions per ICH Q1A(R2), so the final storage statement is supported by data.

Step 8 — Scale-up, validation readiness, and tech transfer

Scale-up success depends on process understanding and documentation:

• Identify CPPs (mixing time, granulation endpoint, drying parameters, compression force)
• Define in-process controls
• Establish acceptable ranges and monitoring strategy

Tech transfer deliverables typically include:

• Master formula and manufacturing instructions
• Control strategy summary
• Method transfer package for QC
• Stability protocol and reporting package
• Development report aligned to CTD Module 3 narrative

Tablet formulation development: a scale-up “handover checklist”

Use this checklist before you run your first scale batch:

• Confirm API PSD control strategy and acceptance ranges
• Lock blend order and lubricant mixing time limits
• Define granulation endpoint criteria (if applicable) and how it is measured
• Define compression window and hardness targets tied to dissolution
• Align test methods and system suitability across development and QC
• Confirm stability pull schedule and sample inventory plan

This reduces “scale-up drift” and preserves dossier consistency.

Common issues and how to prevent them

Dissolution failures after scale-up

Often caused by changes in:

• API PSD or polymorph
• Lubrication time
• Granule density
• Compression force and porosity

Prevention: design a robust dissolution method and build a compression window study early.

Capping/lamination during compression

Often linked to:

• Poor binder selection
• Excessive fines
• Too much elastic recovery

Prevention: adjust granulation, binder system, and compression profile; consider dry granulation route if appropriate.

Stability-driven impurity spikes

Often linked to:

• Reactive excipients
• Residual moisture
• Peroxide content in excipients

Prevention: compatibility screening and targeted stability monitoring, with supplier qualification and incoming material controls.

How Noralixlabs supports tablet formulation development

Noralixlabs executes tablet formulation development with a regulatory-aligned mindset:

• Preformulation and risk-based excipient selection
• Robust process route selection (DC, wet, dry granulation)
• Analytical methods that support stability and dossier needs
• ICH Q1A(R2) stability designs integrated with packaging strategy
• Tech transfer documentation built to be CTD-ready

CTA: Build a tablet program that scales and files cleanly

If you’re developing a new tablet product, troubleshooting dissolution/stability, or preparing for tech transfer, Noralixlabs can help you move from prototype to submission-ready package efficiently.

Contact Noralixlabs to discuss your API profile, target market, and timelines—and we’ll propose a development plan and deliverables checklist.